Altimmune (ALT) Depreciation & Amortization (CF) (2010 - 2026)
Altimmune (ALT) reported Depreciation & Amortization (CF) of $23000.0 for Q1 2026, down 20.69% year-over-year from $29000.0 in Q1 2025, and up 64.29% on a QoQ basis from $14000.0 in Q4 2025.
Altimmune (ALT) has 17 years of Depreciation & Amortization (CF) data on file, last reported at $23000.0 in Q1 2026.
- Quarterly Depreciation & Amortization (CF) fell 20.69% year-over-year to $23000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $94000.0 (down 22.95% YoY) and the FY2025 annual result came in at $100000.0, down 50.0% from the prior year.
- Depreciation & Amortization (CF) improved to $23000.0 in Q1 2026 per ALT's latest filing, from $14000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $137000.0 in Q4 2023 and bottomed at -$552000.0 in Q3 2023.
- The 5-year median for Depreciation & Amortization (CF) is $27000.0 (2025), against an average of -$68117.6.
- The widest annual swing landed in 2023, when Depreciation & Amortization (CF) tumbled 1052.83%; it then soared 380.0% in 2025.
- Tracing ALT's Depreciation & Amortization (CF) over 5 years: stood at -$236000.0 in 2022, then soared by 158.05% to $137000.0 in 2023, then slumped by 103.65% to -$5000.0 in 2024, then soared by 380.0% to $14000.0 in 2025, then soared by 64.29% to $23000.0 in 2026.
- Per Business Quant, the three latest ALT Depreciation & Amortization (CF) figures stand at $23000.0 (Q1 2026), $14000.0 (Q4 2025), and $27000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 1,395.22 |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 55.90 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 123.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 13.55 Mn |
| 10 | Altimmune | 379.61 Mn | 379.61 Mn | - | 23,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 23,000.00 |
| Mar 31, 2026 | 23,000.00 |
| Dec 31, 2025 | 14,000.00 |
| Dec 31, 2025 | 14,000.00 |
| Sep 30, 2025 | 27,000.00 |
| Sep 30, 2025 | 27,000.00 |
| Jun 30, 2025 | 30,000.00 |
| Jun 30, 2025 | 30,000.00 |
| Mar 31, 2025 | 29,000.00 |
| Mar 31, 2025 | 29,000.00 |
| Dec 31, 2024 | -5,000.00 |
| Dec 31, 2024 | -5,000.00 |
| Sep 30, 2024 | 37,000.00 |
| Sep 30, 2024 | 37,000.00 |
| Jun 30, 2024 | 61,000.00 |
| Jun 30, 2024 | 61,000.00 |
| Mar 31, 2024 | 107,000.00 |
| Mar 31, 2024 | 107,000.00 |
| Dec 31, 2023 | 137,000.00 |
| Dec 31, 2023 | 137,000.00 |
| Sep 30, 2023 | -552,000.00 |
| Sep 30, 2023 | -552,000.00 |
| Jun 30, 2023 | -505,000.00 |
| Jun 30, 2023 | -505,000.00 |
| Mar 31, 2023 | -356,000.00 |
| Mar 31, 2023 | -356,000.00 |
| Dec 31, 2022 | -236,000.00 |
| Dec 31, 2022 | -236,000.00 |
| Sep 30, 2022 | -141,000.00 |
| Sep 30, 2022 | -141,000.00 |
| Jun 30, 2022 | 53,000.00 |
| Jun 30, 2022 | 53,000.00 |
| Mar 31, 2022 | 119,000.00 |
| Mar 31, 2022 | 119,000.00 |
| Dec 31, 2021 | 117,000.00 |
| Dec 31, 2021 | 117,000.00 |
| Sep 30, 2021 | 285,000.00 |
| Sep 30, 2021 | 285,000.00 |
| Jun 30, 2021 | 75,000.00 |
| Jun 30, 2021 | 75,000.00 |
| Mar 31, 2021 | 74,000.00 |
| Mar 31, 2021 | 74,000.00 |
| Dec 31, 2020 | 209,946.00 |
| Dec 31, 2020 | 209,946.00 |
| Sep 30, 2020 | 72,887.00 |
| Sep 30, 2020 | 72,887.00 |
| Jun 30, 2020 | 72,689.00 |
| Jun 30, 2020 | 72,689.00 |
| Mar 31, 2020 | 73,356.00 |
| Mar 31, 2020 | 73,356.00 |
| Dec 31, 2019 | 58,507.00 |
| Dec 31, 2019 | 58,507.00 |
| Sep 30, 2019 | 59,415.00 |
| Sep 30, 2019 | 59,415.00 |
| Jun 30, 2019 | 60,622.00 |
| Jun 30, 2019 | 60,622.00 |
| Mar 31, 2019 | 61,277.00 |
| Mar 31, 2019 | 61,277.00 |
| Dec 31, 2018 | 72,418.00 |
| Dec 31, 2018 | 72,418.00 |
| Sep 30, 2018 | 68,771.00 |
| Sep 30, 2018 | 68,771.00 |
| Jun 30, 2018 | 52,466.00 |
| Jun 30, 2018 | 52,466.00 |
| Mar 31, 2018 | 25,062.00 |
| Mar 31, 2018 | 25,062.00 |
| Dec 31, 2017 | 22,643.00 |
| Dec 31, 2017 | 22,643.00 |
| Sep 30, 2017 | 23,364.00 |
| Sep 30, 2017 | 23,364.00 |
| Jun 30, 2017 | 24,861.00 |
| Jun 30, 2017 | 24,861.00 |
| Mar 31, 2017 | 12,966.00 |
| Mar 31, 2017 | 12,966.00 |
| Dec 31, 2016 | 15,833.00 |
| Dec 31, 2016 | 15,833.00 |
| Sep 30, 2016 | 32,235.00 |
| Sep 30, 2016 | 32,235.00 |
| Jun 30, 2016 | 40,435.00 |
| Jun 30, 2016 | 40,435.00 |
| Mar 31, 2016 | 37,701.00 |
| Mar 31, 2016 | 37,701.00 |
| Dec 31, 2015 | 32,806.00 |
| Dec 31, 2015 | 32,806.00 |
| Sep 30, 2015 | 35,005.00 |
| Sep 30, 2015 | 35,005.00 |
| Jun 30, 2015 | 36,687.00 |
| Jun 30, 2015 | 36,687.00 |
| Mar 31, 2015 | 37,106.00 |
| Mar 31, 2015 | 37,106.00 |
| Dec 31, 2014 | 36,686.00 |
| Dec 31, 2014 | 36,686.00 |
| Sep 30, 2014 | 37,125.00 |
| Sep 30, 2014 | 37,125.00 |
| Jun 30, 2014 | 36,208.00 |
| Jun 30, 2014 | 36,208.00 |
| Mar 31, 2014 | 39,939.00 |
| Mar 31, 2014 | 39,939.00 |
| Dec 31, 2013 | 43,438.00 |
| Dec 31, 2013 | 43,438.00 |
| Sep 30, 2013 | 44,593.00 |
| Sep 30, 2013 | 44,593.00 |
| Jun 30, 2013 | 41,854.00 |
| Jun 30, 2013 | 41,854.00 |
| Mar 31, 2013 | 52,602.00 |
| Mar 31, 2013 | 52,602.00 |
| Dec 31, 2012 | 69,105.00 |
| Dec 31, 2012 | 69,105.00 |
| Sep 30, 2012 | 72,453.00 |
| Sep 30, 2012 | 72,453.00 |
| Jun 30, 2012 | 76,448.00 |
| Jun 30, 2012 | 76,448.00 |
| Mar 31, 2012 | 85,910.00 |
| Mar 31, 2012 | 85,910.00 |
| Dec 31, 2011 | 112,260.00 |
| Dec 31, 2011 | 112,260.00 |
| Sep 30, 2011 | 114,494.00 |
| Sep 30, 2011 | 114,494.00 |
| Jun 30, 2011 | 116,690.00 |
| Jun 30, 2011 | 116,690.00 |
| Mar 31, 2011 | 117,629.00 |
| Mar 31, 2011 | 117,629.00 |
| Dec 31, 2010 | 262,447.00 |
| Dec 31, 2010 | 262,447.00 |
| Sep 30, 2010 | 258,231.00 |
| Sep 30, 2010 | 258,231.00 |
| Jun 30, 2010 | 254,440.00 |
| Jun 30, 2010 | 254,440.00 |